RAF1
Top inhibitors
| Drug | Inhibition % | Gini |
|---|---|---|
| Ripretinib | 100.0 | 0.67 |
| Apatinib | 100.0 | 0.70 |
| Sorafenib | 100.0 | 0.78 |
| Ponatinib | 100.0 | 0.53 |
| Regorafenib | 99.9 | 0.72 |
| Upadacitinib | 99.9 | 0.66 |
| Dabrafenib | 99.8 | 0.63 |
| Umbralisib | 99.8 | 0.67 |
| Encorafenib | 99.7 | 0.76 |
| Nilotinib | 98.3 | 0.77 |
| Rabusertib | 95.6 | 0.69 |
| Pazopanib | 95.5 | 0.67 |
| Vemurafenib | 95.2 | 0.60 |
| Dasatinib | 74.3 | 0.70 |
| Imatinib | 74.0 | 0.72 |
Known variants
Cancer associations
| Mutation | Cancer type | Organ | Source |
|---|---|---|---|
R391W | carcinoid-endocrine_tumour_lung | Lung | https://doi.org/10.1093/nar/gkaa945 |
R391W | lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | https://doi.org/10.1093/nar/gkaa945 |
R391W | malignant_melanoma_skin | Skin | https://doi.org/10.1093/nar/gkaa945 |
R391W | CLLE-ES | Blood/Lymphatic System | https://doi.org/10.1093/nar/gkaa945 |
R391W | KIRP-US | Kidney | https://doi.org/10.1093/nar/gkaa945 |
R391W | KIRP | Kidney | https://doi.org/10.1093/nar/gkaa945 |